Actelion Adds to PAH Franchise with IV drug from GeneraMedix
This article was originally published in The Pink Sheet Daily
Executive Summary
Buying GeneraMedix’s IV formulation of epoprostenol allows Actelion to leverage its infrastructure and experience in PAH and strengthen its lead in this increasingly crowded market.